Piper Jaffray Cuts Price Target on Antares Pharma (ATRS) Following 2Q

Go back to Piper Jaffray Cuts Price Target on Antares Pharma (ATRS) Following 2Q

Antares Pharma's (ATRS) CFO Resigns

August 11, 2016 7:15 AM EDT

Antares Pharma (NASDAQ: ATRS) disclosed in an SEC filing:

On August 5, 2016, Antares Pharma, Inc. (the Company) received a written notice of resignation from James E. Fickenscher, the Companys Senior Vice President and Chief Financial Officer. Mr. Fickenschers resignation will become effective September 4, 2016.... More

Antares Pharma (ATRS) Reports In-Line Q2 EPS

August 9, 2016 7:50 AM EDT

Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

... More